Cancer Biotherapeutics
 
MOC Mobile Banner  
2016 Archived Content

2016 Speaking Faculty

Amir R. Aref, Ph.D., Scientist, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School

James Baker, Ph.D., Senior Lecturer, Chemistry, UCL

Marina Bacac, Ph.D., Head, Cancer Immunotherapy, Roche Innovation Center Zurich.

Onur Boyman, M.D., Professor, Chairman and Director, Immunology University Hospital Zurich

Kerry Chester, Ph.D., Professor, UCL Cancer Institute

Joe Conner, Ph.D., CSO, Virttu Biologics Ltd.

Stefan Dübel, Ph.D., Managing Director and Professor, Biotechnology, Technische Universität Braunschweig

Peter Ellmark, Ph.D., Principal Scientist, Alligator Bioscience

Nicolas Fischer, Ph.D., Head, Research, Novimmune SA

Björn Frendéus, Ph.D., CSO, BioInvent International AB

Matthias Friedrich, Ph.D., Director, Nonclinical Development, Amgen Research (Munich) GmbH

John Haurum, M.D., D.Phil., CEO, F-star Biotechnology Ltd.

Mads Hald Andersen, Ph.D., D.Sc. Tech., Professor, Director, Centre for Cancer Immune Therapy, Copenhagen University Hospital

Oliver Hill, Ph.D., Vice President, Molecular Biology, Apogenix GmbH

Holbrook E. Kohrt, M.D., Ph.D., Assistant Professor, Oncology, Stanford University

Marie Kosco-Vilbois, Ph.D., CSO, Novimmune SA

Roland Kontermann, Ph.D., Professor, Biomedical Engineering, Cell Biology and Immunology, University of Stuttgart

Peter Lowe, Ph.D., Project Leader, Molecular and Cellular Biology, Institut de Recherche, Pierre Fabre

John McCafferty, Ph.D., CEO, IONTAS

Jennifer Michaelson, Ph.D., Director, Research, Tumour Biology, Jounce Therapeutics

Philipp Müller, Ph.D., Lab Head, Biomedicine University & University Hospital of Basel

Dario Neri, Ph.D., Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH), Zurich

Sujiet Puthenveetil, Ph.D., Principal Scientist, Medicinal Chemistry, Pfizer, Inc.

Sergio A. Quezada, Ph.D., Professorial Research Fellow, Research Haematology, University College London Cancer Institute

Brian Soper, Ph.D., Technical Information Scientist, The Jackson Laboratory

Kris Thielemans, Ph.D., Professor, Immunology & Oncology, Vrije Universiteit Brussel

Mark Throsby, Ph.D., CSO, Merus BV

Andrea van Elsas, Ph.D., CSO, BioNovion B.V.

Nicolai Wagtmann, Ph.D., CSO, Innate Pharma

Luise Weigand, Ph.D., Team Leader, Cell Biology/Research Management, Immunocore Ltd.

Ann White, Ph.D., Senior Research Fellow, Faculty of Medicine, Cancer Sciences Unit, University of Southampton

Robert Williams, Ph.D., Chief Drug Development Scientist, Cancer Research UK Centre for Drug Development

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Save the Date!
20-24 March 2017


Download Event Brochure


Premier Sponsors

Jackson Laboratory


View All Sponsors


View Media Partners



CONFERENCE PROGRAMS


DINNER COURSES

"Some of the most promising emergent biopharmaceuticals for cancer therapy include agents capable of selective homing to the tumor environment, as well as drugs capable of selective activation of the immune system against malignant cells."

Dario Neri, Ph.D., Swiss Federal Institute of Technology


"You have put together an amazing meeting."

Sergio A. Quezada, Ph.D., UCL Cancer Institute